Novo Nordisk signs $3.3bn deal to acquire Dicerna Pharmaceuticals
Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) ... Read More
Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment
Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal ... Read More